120 related articles for article (PubMed ID: 6090353)
41. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721.
Calabro-Jones PM; Fahey RC; Smoluk GD; Ward JF
Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Jan; 47(1):23-7. PubMed ID: 2982751
[TBL] [Abstract][Full Text] [Related]
42. Thin layer chromatographic and colorimetric methods for monitoring the purity of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721).
Washburn LC; Hayes RL
Anal Chem; 1974 Dec; 46(14):2231-2. PubMed ID: 4440864
[No Abstract] [Full Text] [Related]
43. Variation in normal tissue responsiveness to WR-2721.
Yuhas JM; Afzal SM; Afzal V
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1537-9. PubMed ID: 6090357
[TBL] [Abstract][Full Text] [Related]
44. Thermospray liquid chromatography mass spectrometry of thiol radioprotective agents: characteristic spectra.
Walden TL; Buchner J; Pizzitola V; Blakely WF
Pharmacol Ther; 1988; 39(1-3):219-21. PubMed ID: 2849128
[No Abstract] [Full Text] [Related]
45. Radioprotection against cataract formation by WR-77913 in gamma-irradiated rats.
Menard TW; Osgood TB; Clark JI; Spence AM; Steele JE; Krohn KA; Livesey JC
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1483-6. PubMed ID: 3019964
[TBL] [Abstract][Full Text] [Related]
46. Equilibrium dialysis studies of the binding of radioprotector compounds to DNA.
Smoluk GD; Fahey RC; Ward JF
Radiat Res; 1986 Aug; 107(2):194-204. PubMed ID: 3018831
[TBL] [Abstract][Full Text] [Related]
47. Intraduodenal administration of ethiofos (WR-2721): dose proportionality study in the rhesus monkey.
Geary RS; Swynnerton NF; Miller MA; Mangold DJ; Ludden T
Res Commun Chem Pathol Pharmacol; 1989 Aug; 65(2):147-59. PubMed ID: 2555852
[TBL] [Abstract][Full Text] [Related]
48. Determination of WR-1065 in human blood by high-performance liquid chromatography following fluorescent derivatization by a maleimide reagent ThioGlo3.
Chen J; Lu Z; Lawrence TS; Smith DE
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 May; 819(1):161-7. PubMed ID: 15797534
[TBL] [Abstract][Full Text] [Related]
49. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2.
Utley JF; Marlowe C; Waddell WJ
Radiat Res; 1976 Nov; 68(2):284-91. PubMed ID: 185642
[No Abstract] [Full Text] [Related]
50. WR-2721 inhibition of radiation-induced prostaglandin excretion in rats.
Donlon M; Steel L; Helgeson EA; Wolfe WW; Catravas GN
Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Feb; 47(2):205-12. PubMed ID: 2984129
[TBL] [Abstract][Full Text] [Related]
51. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.
Treskes M; Holwerda U; Nijtmans LG; Pinedo HM; van der Vijgh WJ
Cancer Chemother Pharmacol; 1992; 29(6):467-70. PubMed ID: 1314713
[TBL] [Abstract][Full Text] [Related]
52. Protection of mice against fission neutron irradiation by WR-2721 or WR-151327.
Steel LK; Jacobs AJ; Giambarresi LI; Jackson WE
Radiat Res; 1987 Mar; 109(3):469-78. PubMed ID: 3031721
[TBL] [Abstract][Full Text] [Related]
53. Synthesis, biodistribution, and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)ethylphosphorothioic acid (WR-3689).
Rasey JS; Krohn KA; Grunbaum Z; Spence AM; Menard TW; Wade RA
Radiat Res; 1986 Jun; 106(3):366-79. PubMed ID: 3012625
[TBL] [Abstract][Full Text] [Related]
54. Protein binding of N-2-mercaptoethyl-1,3-diaminopropane via mixed disulfide formation after oral administration of WR 2721.
Tabachnik NF; Blackburn P; Peterson CM; Cerami A
J Pharmacol Exp Ther; 1982 Feb; 220(2):243-6. PubMed ID: 6276531
[TBL] [Abstract][Full Text] [Related]
55. Modulation of cis-platinum renal toxicity by the radioprotective agent WR 2721.
Jordan SW; Yuhas JM; Glick J
Exp Mol Pathol; 1982 Jun; 36(3):297-305. PubMed ID: 6282619
[No Abstract] [Full Text] [Related]
56. Sodium hydrogen-S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913): toxicity and bone marrow radioprotection.
Mendiondo OA; Connor AM; Grigsby P
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):553-5. PubMed ID: 6286552
[TBL] [Abstract][Full Text] [Related]
57. Isoproterenol in comparison to WR-2721 as a chemoradioprotector of the rat parotid gland.
Sodicoff M; Conger AD; Pratt NE
Invest Radiol; 1979; 14(2):166-70. PubMed ID: 225291
[TBL] [Abstract][Full Text] [Related]
58. Radioprotective activity of ethylcellulose microspheres containing WR 2721, after oral administration.
Fatome M; Courteille F; Laval JD; Roman V
Int J Radiat Biol Relat Stud Phys Chem Med; 1987 Jul; 52(1):21-9. PubMed ID: 3036725
[TBL] [Abstract][Full Text] [Related]
59. Behavioral toxicity and efficacy of WR-2721 as a radioprotectant.
Bogo V; Jacobs AJ; Weiss JF
Radiat Res; 1985 Nov; 104(2 Pt 1):182-90. PubMed ID: 3001816
[TBL] [Abstract][Full Text] [Related]
60. HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721).
Thompson DC; Wyrick SD; Holbrook DJ; Chaney SG
Biochem Pharmacol; 1995 Oct; 50(9):1413-9. PubMed ID: 7503792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
